دورية أكاديمية

LBA60 Evaluation of gemcitabine and paclitaxel versus gemcitabine alone after FOLFIRINOX failure or intolerance in metastatic pancreatic ductal adenocarcinoma: Results of the randomized phase III PRODIGE 65 - UCGI 36 - GEMPAX UNICANCER study

التفاصيل البيبلوغرافية
العنوان: LBA60 Evaluation of gemcitabine and paclitaxel versus gemcitabine alone after FOLFIRINOX failure or intolerance in metastatic pancreatic ductal adenocarcinoma: Results of the randomized phase III PRODIGE 65 - UCGI 36 - GEMPAX UNICANCER study
المؤلفون: de la Fouchardiere, C., Malka, D., Chabaud, S., Raimbourg, J., Botsen, D., Launay, S., Evesque, L., Vienot, A., Perrier, H., Jary, M., Rinaldi, Y., Bergouignan, C. Coutzac, Bachet, J-B., Neuzillet, C., Williet, N., Desgrippes, R., Brard, G., Lachaux, N., Bouche, O., Ghiringhelli, F.
المصدر: In Annals of Oncology September 2022 33 Supplement 7:S1426-S1426
قاعدة البيانات: ScienceDirect
الوصف
تدمد:09237534
DOI:10.1016/j.annonc.2022.08.062